Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 5/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.43 |
| ▸ | TLR4 | O00206 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL983385 | 0.94 | TLR4 (0.45) | PARP15PARP10TLR4TLR2MAOA | |
| SCHEMBL7975035 | 0.80 | ALDH1A1 (0.70) | ALDH1A1TP53CYP3A4TSHRSMN1; SMN2 | |
| SCHEMBL984346 | 0.78 | TP53 (0.49) | ALDH1A1TP53CYP3A4TSHRSMN1; SMN2 | |
| SCHEMBL5346832 | 0.76 | SMN1; SMN2 (0.39) | ALDH1A1TP53CYP3A4TSHRSMN1; SMN2 | |
| SCHEMBL1276629 | 0.75 | MAOB (0.46) | MAOAMAOBALDH1A1TP53CYP3A4 | |
| SCHEMBL5725738 | 0.75 | SMN1; SMN2 (0.38) | MAOAMAOBALDH1A1TP53CYP3A4 | |
| SCHEMBL984529 | 0.75 | KMT2A (0.46) | ALDH1A1TP53CYP3A4TSHRSMN1; SMN2 | |
| SCHEMBL767828 | 0.75 | CYP3A4 (0.39) | MAOBALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL10188240 | 0.74 | ALDH1A1 (0.49) | PARP15PARP10TLR4TLR2ALDH1A1 | |
| SCHEMBL16180720 | 0.74 | MAOB (0.50) | PARP15PARP10TLR4TLR2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2247594-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | PARP15 227/4885PARP10 1059/4885TLR4 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.